Perrigo And Sol-Gel Face Up To Duobrii Lawsuit

ANDA Filed By Perrigo In July

 
• By Dean Rudge

Collaboration partners Perrigo and Sol-Gel Technologies face legal action stemming from Perrigo’s filing of an ANDA for generic Duobrii lotion for the treatment of plaque psoriasis in adults.

Gavel
Perrigo sent the originator a Paragraph IV patent challenge certification on 23 July • Source: Shutterstock

Perrigo must face a lawsuit in the US over its proposed generic to Bausch Health’s Duobrii (halobetasol propionate/tazarotene) lotion for the treatment of plaque psoriasis in adults, the company’s collaboration partner Sol-Gel Technologies has confirmed.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin